BIOCON Financial Statement Analysis
|
||
|
The Revenues of BIOCON have increased by 36.54% YoY .
The Earnings Per Share (EPS) of BIOCON has increased by 121.30 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
BIOCON Last 5 Annual Financial Results
[BOM: 532523|NSE : BIOCON]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹11,174 Cr | ₹8,184 Cr | ₹7,143 Cr | ₹6,301 Cr | ₹5,514 Cr |
| Expenses | ₹9,055 Cr | ₹6,691 Cr | ₹5,841 Cr | ₹5,044 Cr | ₹4,391 Cr |
| Operating Profit (Excl OI) | ₹2,120 Cr | ₹1,493 Cr | ₹1,302 Cr | ₹1,257 Cr | ₹1,124 Cr |
| Other Income | ₹768 Cr | ₹690 Cr | ₹605 Cr | ₹508 Cr | ₹414 Cr |
| Interest | ₹419 Cr | ₹68 Cr | ₹58 Cr | ₹65 Cr | ₹71 Cr |
| Depreciation | ₹1,113 Cr | ₹814 Cr | ₹715 Cr | ₹552 Cr | ₹448 Cr |
| Profit Before Tax | ₹897 Cr | ₹983 Cr | ₹1,068 Cr | ₹1,215 Cr | ₹1,215 Cr |
| Profit After Tax | ₹643 Cr | ₹772 Cr | ₹846 Cr | ₹900 Cr | ₹1,003 Cr |
| Consolidated Net Profit | ₹463 Cr | ₹648 Cr | ₹741 Cr | ₹748 Cr | ₹905 Cr |
| Earnings Per Share (Rs) | ₹8.52 | ₹3.85 | ₹5.40 | ₹6.17 | ₹6.24 |
| PAT Margin (%) | 8.69 | 5.70 | 9.40 | 11.85 | 14.28 |
| ROE(%) | 7.00 | 4.98 | 9.83 | 12.03 | 14.26 |
| ROCE(%) | 7.03 | 5.37 | 8.30 | 10.56 | 14.35 |
| Total Debt/Equity(x) | 0.81 | 1.01 | 0.60 | 0.58 | 0.40 |
Key Financials |
||
| Market Cap | : | ₹ 41,396.7 Cr |
| Revenue (TTM) | : | ₹ 14,894.1 Cr |
| Net Profit(TTM) | : | ₹ 1,891.9 Cr |
| EPS (TTM) | : | ₹ 15.8 |
| P/E (TTM) | : | 21.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BIOCON | -0.9% | 2.5% | 35.9% |
| SUN PHARMACEUTICAL INDUSTRIES | 1% | 0.7% | 47.3% |
| CIPLA | 0.3% | -1.8% | 19.6% |
| DR REDDYS LABORATORIES | 6% | 11.8% | 20.3% |
| ZYDUS LIFESCIENCES | -1.5% | -0.1% | 47% |
| DIVIS LABORATORIES | -1.1% | -5.8% | 61.7% |
| MANKIND PHARMA | 3.7% | 11.4% | 59.4% |
| TORRENT PHARMACEUTICALS | 0.6% | 4.1% | 59.5% |
| LUPIN | 3.3% | 2.9% | 75.9% |
BIOCON Revenues
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | 36.54 % |
| 5 Yr CAGR | 19.31 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹11,174 Cr | 36.54 | |
| Mar2023 | ₹8,184 Cr | 14.57 | |
| Mar2022 | ₹7,143 Cr | 13.37 | |
| Mar2021 | ₹6,301 Cr | 14.26 | |
| Mar2020 | ₹5,514 Cr | - | |
BIOCON Operating Profit
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | 42.00 % |
| 5 Yr CAGR | 17.19 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,120 Cr | 42.00 | |
| Mar2023 | ₹1,493 Cr | 14.63 | |
| Mar2022 | ₹1,302 Cr | 3.59 | |
| Mar2021 | ₹1,257 Cr | 11.85 | |
| Mar2020 | ₹1,124 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 4.00 % |
| 5 Yr CAGR | -1.78 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 18.97% | 4.00 | |
| Mar2023 | 18.24% | 0.05 | |
| Mar2022 | 18.23% | -8.62 | |
| Mar2021 | 19.95% | -2.11 | |
| Mar2020 | 20.38% | - | |
BIOCON Profit After Tax
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | -28.64 % |
| 5 Yr CAGR | -15.45 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹463 Cr | -28.64 | |
| Mar2023 | ₹648 Cr | -12.44 | |
| Mar2022 | ₹741 Cr | -1.03 | |
| Mar2021 | ₹748 Cr | -17.35 | |
| Mar2020 | ₹905 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 52.46 % |
| 5 Yr CAGR | -11.68 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 8.69 % | 52.46 | |
| Mar2023 | 5.7 % | -39.36 | |
| Mar2022 | 9.4 % | -20.68 | |
| Mar2021 | 11.85 % | -17.02 | |
| Mar2020 | 14.28 % | - | |
BIOCON Earnings Per Share (EPS)
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | 121.30 % |
| 5 Yr CAGR | 8.10 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹8.52 | 121.30 | |
| Mar2023 | ₹3.85 | -28.70 | |
| Mar2022 | ₹5.40 | -12.48 | |
| Mar2021 | ₹6.17 | -1.12 | |
| Mar2020 | ₹6.24 | - | |
BIOCON Return on Capital Employed (ROCE)
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | 30.91 % |
| 5 Yr CAGR | -16.34 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 7.03% | 30.91 | |
| Mar2023 | 5.37% | -35.30 | |
| Mar2022 | 8.3% | -21.40 | |
| Mar2021 | 10.56% | -26.41 | |
| Mar2020 | 14.35% | - | |
BIOCON Share Price vs Sensex
| Current Share Price | : | ₹344.8 |
| Current MarketCap | : | ₹ 41,396.7 Cr |
| Updated EOD on | : | Dec 24,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BIOCON | -0.9% |
2.5% |
35.9% |
| SENSEX | -2.7% |
-0.8% |
9.9% |
BIOCON related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 0.3% | 2.6% | 43.7% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE 200 | -3% | 0.2% | 15.2% |
| S&P BSE 250 LARGEMIDCAP | -3% | 0.3% | 15.4% |
| S&P BSE LARGE MIDCAP | -3% | 0.3% | 14.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 2.2% | 2.7% | 37.6% |
| NIFTY HEALTHCARE | 1% | 3.4% | 39.6% |
| NIFTY 500 | -3% | 0.8% | 16.9% |
| NIFTY500 MULTICAP 50:25:25 | -3% | 1.8% | 19.9% |
| NIFTY LARGE MIDCAP 250 | -3% | 1.5% | 19.4% |
You may also like the below Video Courses
FAQ about BIOCON Financials
How the annual revenues of BIOCON have changed ?
The Revenues of BIOCON have increased by 36.54% YoY .
How the Earnings per Share (EPS) of BIOCON have changed?
The Earnings Per Share (EPS) of BIOCON has increased by 121.30 % YoY .
Check out Intrinsic Value of Peers of BIOCON
Compare Stock Analytics of Peers of BIOCON
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
